This makes it possible to screen cancers feasible for receiving CAP treatment and enables the design of innovative therapeutics via stimulating EGFR(Y1068) phosphorylation instead of blocking the whole EGFR receptor for treating cancers with little adverse effect. The gene discussed is EGFR; the disease is cancer.